Evidence Snapshot

KLE

CHEMBL2366239 CELL-LINE Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:18Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:31 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2366239

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats KLE as ChEMBL target CHEMBL2366239. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

KLE

CELL-LINE · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2366239

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why KLE matters

As of 2026-09-13

KLE is reviewed as KLE; the current evidence base includes 22 approved drugs, 150 compounds, and 45 assays, with lead potency reaching pChEMBL 7.6.

Protein context

KLE

Review this target as KLE.

Protein source · UniProt accession via ChEMBL component mapping

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 22 approved drugs, 150 compounds, and 45 assays for this target. The dominant activity type is IC50. CHEMBL3545252 is the current potency anchor at pChEMBL 7.6.

Use CHEMBL3545252 as the tractability anchor when discussing potency (pChEMBL 7.6).

Activity source · ChEMBL 36 via Core Engine

22 approved pChEMBL 7.6

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why KLE matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

150

Total Compounds

Total Assays

Approved Drugs

IC50: 147.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL3545252	7.6	IC50	Approved
No preferred name CHEMBL94657	7.4	IC50	Clinical
No preferred name CHEMBL300389	7.2	IC50	—
No preferred name CHEMBL1256459	7.2	IC50	—
No preferred name CHEMBL96926	7.2	IC50	—